



PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 44984

Title: Beneficial effects of losartan or telmisartan on the local hepatic renin-angiotensin system to counter obesity in an experimental model

Reviewer’s code: 03262371

Reviewer’s country: Iran

Science editor: Jia-Ping Yan

Date sent for review: 2018-12-11

Date reviewed: 2018-12-16

Review time: 9 Hours, 5 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	(General priority)	Peer-reviewer’s expertise on the topic of the manuscript:
<input type="checkbox"/> Grade E: Do not publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Minor revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> General
		<input type="checkbox"/> Rejection	<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Dear editor Thanks for your invitation. I read the manuscript entitled “Beneficial effects of losartan or telmisartan on the local hepatic renin-angiotensin system to counter obesity in an experimental model” and tried for doing an assessment. My comments are



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

as follow: Overall comments The manuscript is well written and I found no grammatical and spelling error. I also checked some of paragraphs with google and found no cases of plagiarism. Abstract: The abstract of the manuscript has a good introduction and clearly presents the aim of the study. The methods have been well explained. I wish I could see numbers and statistics in the results part instead of interpretation and explaining mechanisms which should be in conclusion section or be omitted. Additionally, I think the keyword AT1r is not suitable and should be spell out. A keyword, showing the animal model of the study, should also be added. Main text: The introduction section explains the background of the issue and propose the aim of the study well. I'm not familiar with some parts of the methods but design, sampling, randomization, ethical issues, and statistical analysis have been well presented and explained. I have no comments on the results and discussion sections and the references are also relevant and up to dated. Final Comments: The project can be accepted for publication after minor revisions. Best wishes Reviewer

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

[Y] No



PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 44984

Title: Beneficial effects of losartan or telmisartan on the local hepatic renin-angiotensin system to counter obesity in an experimental model

Reviewer’s code: 02544416

Reviewer’s country: Serbia

Science editor: Jia-Ping Yan

Date sent for review: 2018-12-29

Date reviewed: 2019-01-02

Review time: 11 Hours, 4 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	(General priority)	Peer-reviewer’s expertise on the topic of the manuscript:
<input type="checkbox"/> Grade E: Do not publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Minor revision	<input checked="" type="checkbox"/> Advanced
		<input checked="" type="checkbox"/> Major revision	<input type="checkbox"/> General
		<input type="checkbox"/> Rejection	<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

I read with great interest the manuscript entitled “Beneficial effects of losartan or telmisartan on the local hepatic renin-angiotensin system to counter obesity in an experimental model”. The manuscript is well written and adequately structured. But I



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

have some concerns regarding the quality. The number of mice included in the study is small. McPherson S and co-authors published an article entitled “A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis” where 45 patients were enrolled, and this number was too small to get some valid conclusion, so for experimental studies the limitation for human studies could be exceed, in order to get valid data and conclusions. But the number of experimental subjects is not a limitation factor for publishing. I am missing assessment of liver fibrosis/steatosis and the authors should or add this data or explain in detail why this data are missing. I would suggest comparing their results with results published by Alam S et al. Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial. Saudi J Gastroenterol. 2016 Jan-Feb;22(1):69-76 and Zhang QZ et al. Effects of telmisartan on improving leptin resistance and inhibiting hepatic fibrosis in rats with non-alcoholic fatty liver disease. Exp Ther Med. 2017 Sep;14(3):2689-2694.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com